Valuation: ACLS THER

Market Cap 649M 577M 539M 491M 925M 62.5B 938M 6.52B 2.53B 31.83B 2.44B 2.38B 102B P/E 2026 *
-6.82x
P/E 2027 * -5.61x
Enterprise Value 496M 441M 412M 375M 707M 47.76B 717M 4.98B 1.93B 24.32B 1.86B 1.82B 78.12B EV / Sales 2026 *
78.3x
EV / Sales 2027 * 94.2x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 16/01/2024
President 67 17/11/2024
Director of Finance/CFO 39 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2022
Director/Board Member 50 31/08/2014
Director/Board Member 59 31/08/2016
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-1.87%+4.53%+31.65%+24.63% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.71%-0.08%+53.43%+154.48% 44.09B
Weighted average by Cap. -0.27%+0.11%+57.98%+145.92%

Financials

2026 *2027 *
Net sales 6.34M 5.63M 5.26M 4.8M 9.03M 610M 9.16M 63.69M 24.66M 311M 23.8M 23.28M 998M 5.34M 4.74M 4.43M 4.04M 7.61M 514M 7.71M 53.64M 20.76M 262M 20.04M 19.61M 841M
Net income -90.33M -80.23M -75.03M -68.37M -129M -8.7B -130M -908M -351M -4.43B -339M -332M -14.23B -112M -99.78M -93.31M -85.03M -160M -10.82B -162M -1.13B -437M -5.51B -422M -413M -17.69B
Net Debt -153M -136M -127M -116M -218M -14.74B -221M -1.54B -596M -7.51B -575M -562M -24.11B -147M -130M -122M -111M -209M -14.11B -212M -1.47B -570M -7.19B -550M -538M -23.08B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-